EUVIMEDEUVIMED entdecken
Multizentrische Studie

Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real‐World Study

Ben Varon, Ron Ram, Avichai Shimoni, Batia Avni, Sigal Grisariu, Vered Stavi, Yael Bar-On, Moshe Yeshurun, Ronit Elhasid, Aharon Gefen, Asaf Yanir iD, Odelia Amit und 3 weitere

Hematological Oncology · 2026

DOI: 10.1002/hon.70202 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Hematological Oncology, 2026. Verfasst von Ben Varon und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Center and Technion-Israel Institute of Technology, Haifa, Israel. Hauptthemen laut MEDLINE: Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Protein Kinase Inhibitors. Die Arbeit nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic graft‐versus‐host disease (cGVHD) is the primary contributor to morbidity and mortality following allogeneic stem cell transplantation (ASCT). Belumosudil, a ROCK2 inhibitor, was approved for the cGVHD treatment after at least two prior lines of systemic therapy, based on prospective data. The current study evaluated the real‐world efficacy and safety of belumosudil across all major adult and pediatric SCT centers in Israel. This retrospective study included all consecutive patients with cGVHD treated with belumosudil via compassionate use programs at nine centers. Key baseline characteristics, ASCT details, and cGVHD features were collected from patients' electronic medical records. The analyzed outcomes encompassed overall response rate (ORR), glucocorticoid dose reduction, failure‐free survival (FFS), and overall survival (OS). Data on the safety and tolerability of this therapy were also assessed. The cohort included 45 heavily pretreated (median of 4 prior systemic therapies) patients at a median age of 46 (range, 4–75) years. Severe cGVHD with multi‐organ involvement was documented in 84.4% of patients. The ORR was 55.6% ( n = 25), with 6.7% achieving complete response and 48.9% — partial response. The median time to the best response was 100 days. A significant reduction in the glucocorticoid dosage was observed, with the median dose decreasing from 0.29 mg/kg/day at baseline to 0.02 mg/kg/day at the last follow‐up. The 6‐month and estimated 12‐month OS rates were 95% and 75%, respectively. The most common adverse event was pulmonary infections (17.8%); only one patient discontinued treatment due to an adverse event. Female sex was associated with a borderline statistically significant improvement in FFS. Results of this study demonstrate that belumosudil is effective and well‐tolerated even in a heavily pretreated real‐world patient population with severe and refractory cGVHD. The observed response rates, glucocorticoid dose reductions, and encouraging survival outcomes point to belumosudil as a crucial therapeutic option for this challenging condition.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationProtein Kinase InhibitorsHumansFemaleMaleRetrospective StudiesAdultMiddle AgedChronic DiseaseAdolescentAgedYoung AdultChildChild, PreschoolTreatment OutcomeAcetamides

Stichwörter der Autor:innen

allogeneic stem cell transplantationbelumosudilchronic graft‐versus‐host disease

Substanzen

belumosudilProtein Kinase InhibitorsAcetamides

Autor:innen und Institutionen

  • Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Center and Technion-Israel Institute of Technology, Haifa, Israel.
  • Department of Hematology and Bone Marrow Transplantation, Sourasky Medical Center and Gray Faculty of Medicine and Health Science, Tel Aviv University, Tel Aviv, Israel.
  • Department of Hematology and Bone Marrow Transplantation, Chaim Sheba Medical Center and Gray Faculty of Medicine and Health Science, Tel Aviv University, Tel Aviv, Israel.
  • Bone Marrow Transplantation and Cancer Immunotherapy Department, Hadassah University Medical Center and Faculty of Medicine, the Hebrew University of Jerusalem, Jerusalem, Israel.
  • Department of Hematology and Bone Marrow Transplantation, Soroka University Medical Center, Beer Sheva, Israel.
  • Department of Hematology and Bone Marrow Transplantation, Shaare Zedek Medical Center, Jerusalem, Israel.

ORCID-Profile: Asaf Yanir, Israel Henig, Tsila Zuckerman

Zitieren

APA

Varon, B., Ram, R., Shimoni, A., Avni, B., Grisariu, S., Stavi, V., Bar-On, Y., Yeshurun, M., Elhasid, R., Gefen, A., Yanir, A., Amit, O., Yehudai-Ofir, D., Henig, I., & Zuckerman, T. (2026). Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real‐World Study. Hematological Oncology. https://doi.org/10.1002/hon.70202

Vancouver

Varon B, Ram R, Shimoni A, Avni B, Grisariu S, Stavi V, et al. Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real‐World Study. Hematological Oncology. 2026. doi:10.1002/hon.70202

BibTeX
@article{Varon2026,
  author = {Varon, Ben and Ram, Ron and Shimoni, Avichai and Avni, Batia and Grisariu, Sigal and Stavi, Vered and Bar-On, Yael and Yeshurun, Moshe and Elhasid, Ronit and Gefen, Aharon and Yanir, Asaf and Amit, Odelia and Yehudai-Ofir, Dana and Henig, Israel and Zuckerman, Tsila},
  title = {Belumosudil in the Management of Heavily Pretreated Prolonged Chronic GVHD: A Retrospective Multicenter Real‐World Study},
  journal = {Hematological Oncology},
  year = {2026},
  doi = {10.1002/hon.70202}
}
Kostenlos starten →